Abstract Library

#2091 Differential Signalling Pathways Drive Therapeutic Resistance in Neuroendocrine Tumors

Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) are insufficient due to poor knowledge of these tumours. Despite showing differentiated features, NETs often exhibit therapeutic resistance to common treatments similarly to other cancers. Although signalling abnormalities have been reported, molecular mechanisms responsible for this resistance phenomenon are yet to be understood.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Romano D, Gerard C, Poizat F, Niccoli P, Barlier A,

Keywords: neuroendocrine tumors, drug resistance, proteomics, kinases, apoptosis,

#1917 Clinical Correlates of Discrepant Results of Chromogranin a versus Serotonin Markers in Patients with Neuroendocrine Tumors

Introduction: Neuroendocrine tumors lead to elevated chromogranin A levels and elevated serotonin markers (urinary 5HIAA and platelet serotonin). These markers are employed for diagnosis and monitoring.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Meijer W

Authors: Meijer W, Bruikman C, Beukeveld G,

Keywords: neuroendocrine tumors, chromogranin A, urinary 5HIAA, platelet serotonin,

#1739 A Kinomic Approach to Identify Signaling Proteins Involved in Drug Resistance in GastroEnteroPancreatic Neuroendocrine Tumors

Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) result in tumour growth stabilization, eventually followed by tumour progression. Thus, despite their original characteristics, NETs exhibit similar resistance features to treatments than other more common tumours.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Romano D

Authors: Romano D, Gerard C, Mondielli G, Lisbonis C, Niccoli P,

Keywords: Neuroendocrine Tumors, Drug resistance, Proteomics, Kinases,